Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (141-150 of 301) with videos related to

Pageof 31
Sort By:
Alzheimer Disease and Associated Disorders|July 2, 2009
Lethality of Alzheimer disease and its impact on nursing home placementHenry Michael Arrighi, Peter J Neumann, Ivan M Lieberburg, et al.
Pharmacoeconomics|April 6, 2004
How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?Bruce R Schackman, Heather Taffet Gold, Patricia W Stone, et al.
Health Policy (Amsterdam, Netherlands)|February 20, 2013
What can we learn from the U.S. expanded end-stage renal disease bundle?James D Chambers, Daniel E Weiner, Sarah K Bliss, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 12, 2013
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disordersPei-Jung Lin, Howard M Fillit, Joshua T Cohen, et al.
Journal of Managed Care & Specialty Pharmacy|November 28, 2018
Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage PoliciesJames D Chambers, Elle F Pope, Colby L Wilkinson, et al.
Health Affairs (Project Hope)|October 8, 2014
Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugsJames D Chambers, Teja Thorat, Junhee Pyo, et al.
Pharmacoeconomics|May 9, 2019
Publication of Decision Model Source Code: Attitudes of Health Economics AuthorsJoanna Emerson, Rachel Bacon, Alma Kent, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2025
Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation ProgramFeng Xie, Ting Zhou, Yue Ma, et al.
Managed Care Interface|August 9, 2006
The economic burden of intracerebral hemorrhage: evidence from managed careMason W Russell, Luke Boulanger, Ashish V Joshi, et al.
Journal of the American Geriatrics Society|June 14, 2016
Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After DiagnosisPei-Jung Lin, Yue Zhong, Howard M Fillit, et al.
Pageof 31

Showing results (141-150 of 301) with videos related to

Sort By:
Pageof 31
Alzheimer Disease and Associated Disorders|July 2, 2009
Lethality of Alzheimer disease and its impact on nursing home placementHenry Michael Arrighi, Peter J Neumann, Ivan M Lieberburg, et al.
Pharmacoeconomics|April 6, 2004
How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?Bruce R Schackman, Heather Taffet Gold, Patricia W Stone, et al.
Health Policy (Amsterdam, Netherlands)|February 20, 2013
What can we learn from the U.S. expanded end-stage renal disease bundle?James D Chambers, Daniel E Weiner, Sarah K Bliss, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 12, 2013
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disordersPei-Jung Lin, Howard M Fillit, Joshua T Cohen, et al.
Journal of Managed Care & Specialty Pharmacy|November 28, 2018
Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage PoliciesJames D Chambers, Elle F Pope, Colby L Wilkinson, et al.
Health Affairs (Project Hope)|October 8, 2014
Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugsJames D Chambers, Teja Thorat, Junhee Pyo, et al.
Pharmacoeconomics|May 9, 2019
Publication of Decision Model Source Code: Attitudes of Health Economics AuthorsJoanna Emerson, Rachel Bacon, Alma Kent, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2025
Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation ProgramFeng Xie, Ting Zhou, Yue Ma, et al.
Managed Care Interface|August 9, 2006
The economic burden of intracerebral hemorrhage: evidence from managed careMason W Russell, Luke Boulanger, Ashish V Joshi, et al.
Journal of the American Geriatrics Society|June 14, 2016
Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After DiagnosisPei-Jung Lin, Yue Zhong, Howard M Fillit, et al.
Pageof 31